Melatonin and breast cancer: Evidences from preclinical and human studies
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
29458781
DOI
10.1016/j.critrevonc.2017.12.018
PII: S1040-8428(17)30088-4
Knihovny.cz E-zdroje
- Klíčová slova
- Breast cancer, Circadian disruption, Immune mechanism, Mechanism of action, Melatonin, Treatment,
- MeSH
- lidé MeSH
- melatonin aplikace a dávkování metabolismus farmakologie MeSH
- nádory prsu farmakoterapie metabolismus MeSH
- prospektivní studie MeSH
- signální transdukce účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- melatonin MeSH
The breast cancer affects women with high mortality and morbidity worldwide. The risk is highest in the most developed world but also is markedly rising in the developing countries. It is well documented that melatonin has a significant anti-tumor activities demonstrated on various cancer types in a plethora of preclinical studies. In breast cancer, melatonin is capable to disrupt estrogen-dependent cell signaling, resulting in a reduction of estrogen-stimulated cells, moreover, it's obvious neuro-immunomodulatory effect in organism was described. Several prospective studies have demonstrated the inverse correlation between melatonin metabolites and the risk of breast cancer. This correlation was confirmed by observational studies that found lower melatonin levels in breast cancer patients. Moreover, clinical studies have showed that circadian disruption of melatonin synthesis, specifically night shift work, is linked to increased breast cancer risk. In this regard, proper light/dark exposure with more selective use of light at night along with oral supplementation of melatonin may have benefits for high-risk women. The results of current preclinical studies, the mechanism of action, and clinical efficacy of melatonin in breast cancer are reviewed in this paper. Melatonin alone or in combined administration seems to be appropriate drug for the treatment of early stages of breast cancer with documented low toxicity over a wide range of doses. These and other issues are also discussed.
Department of Immunology School of Medicine Keimyung University Daegu South Korea
Institute of Histology and Embryology Faculty of Medicine University of Ljubljana Ljubljana Slovenia
University of Oviedo Central University Hospital of Asturias Oviedo Spain
Weill Cornell Medical College in Qatar Qatar Foundation Education City Doha Qatar
Citace poskytuje Crossref.org